Methotrexate is used to treat autoimmune and oncologic diseases in children with Down syndrome. However, increased methotrexate-related toxicity is reported in this population. We evaluated differences in the concentrations and distribution of erythrocyte folates in children with Down syndrome as a potential basis for this enhanced toxicity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247922 | PMC |
| http://dx.doi.org/10.1016/j.jpeds.2020.01.032 | DOI Listing |
Publication Analysis
Top Keywords
children syndrome
12
syndrome potential
8
potential basis
8
basis enhanced
8
altered folate
4
folate homeostasis
4
homeostasis children
4
enhanced methotrexate
4
methotrexate toxicity
4
toxicity methotrexate
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!